Liu Jiang-Kui, Shen Yi-Hui, Liu Xiang-Chuan, Zhang Hui, Wu Hui, Yin Ming
Department of Gastroenterology, The General Hospital of Huabei Petroleum, Renqiu Hebei Province 062552, China.
Zhonghua Gan Zang Bing Za Zhi. 2011 Aug;19(8):614-8. doi: 10.3760/cma.j.issn.1007-3418.2011.08.013.
To investigate the effects of telmisartan on steatohepatitis (NASH) in rats by activating peroxisome proliferator-activated receptor gamma (r). Thirty male SD rats were randomized into normal control group, NASH control group and telmisartan prevention group. Normal control group was given standard food and the other two groups were given high fat diet for 16 weeks to induce NASH. Prevention group was given telmisartan (5 mg.kg-1.d-1) for 4 weeks by intragastric adminstration after 12 weeks. At the end of the 16th week, all the rats were sacrificed. Pathological changes of liver were observed by optical microscopy. Serum alanine aminotransferase(ALT), aspartate aminotransferase(AST), fasting blood glucose(FBG), fasting insulin(FINS), HOMA-IR(homeostasis model assessment insulin resistance), Serum TNF-a and adiponectin were detected and analyzed.Western blot and RT-PCR were used to detect PPARr expression in hepatic tissues on protein and mRNA levels. (1) Rats were successfully modeled. The liver tissue samples were divided into 4 degrees (F0 - 4) based on total fatty degeneration of liver cells.There was one rat reached F3 and nine rats reached F4 in NASH group, one rat reached F1, six rats reached F2 and three rats reached F3 in prevention group. Inflammatory activity scores of hepatic tissues in the model group were 2.67+/-0.25, while that in the control group was 0 (U=15 and P is less than to 0.01), in the prevention group were 2.67+/-0.25 and 1.36+/-0.12 (U=24 and P is less than to 0.05 ). (2) The levels of serum ALT, AST, FBG, FINS, TNFa and HOMA-IR in the model group were increased than those in the control group( the vaules of q were 13.130, 6.472, 6.909, 26.619, 14.591 and 49.683 respectively, P less than 0.01). The levels of serum ALT, FINS, FBG, TNFa and HOMA-IR in the prevention group were decreased as compared to the model group (the vaules of q were 7.024, 4.145, 14.829, 13.195 and 31.991 respectively, P less than 0.01 ). (3) The serum adiponectin, PPARrmRNA and protein in liver tissues of the model group were lower than those in the control group (q values were 10.696, 8.679 and 16.762 respectively, P is less than to 0.05).The data in the prevention group were higher as compared to the model group(q values were 3.879,3.079,6.400, P is less than to 0.05 respectively). HOMA-IR was positively correlated with the expression of TNFa but negatively correlated with the expression of adiponectin (r = 0.927, P is less than to 0.01; r = -0.891, P is less than to 0.01, respectively). Telmisartan may has preventive effect on rats with steatohepatitis (NASH) by a mechanism of activating peroxisome proliferator-activated receptor r.
通过激活过氧化物酶体增殖物激活受体γ(PPARγ)研究替米沙坦对大鼠非酒精性脂肪性肝炎(NASH)的影响。将30只雄性SD大鼠随机分为正常对照组、NASH对照组和替米沙坦预防组。正常对照组给予标准饲料,另外两组给予高脂饲料16周以诱导NASH。预防组在12周后通过灌胃给予替米沙坦(5mg·kg-1·d-1),持续4周。在第16周结束时,处死所有大鼠。通过光学显微镜观察肝脏的病理变化。检测并分析血清丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、空腹血糖(FBG)、空腹胰岛素(FINS)、稳态模型评估胰岛素抵抗(HOMA-IR)、血清肿瘤坏死因子-α(TNF-α)和脂联素。采用蛋白质印迹法和逆转录-聚合酶链反应(RT-PCR)检测肝组织中PPARγ在蛋白和mRNA水平的表达。(1)大鼠建模成功。根据肝细胞总脂肪变性情况将肝组织样本分为4度(F0-4)。NASH组有1只大鼠达到F-3,9只大鼠达到F-4;预防组有1只大鼠达到F-1,6只大鼠达到F-2,3只大鼠达到F-3。模型组肝组织炎症活动评分为2.67±0.25,而对照组为0(U=15,P<0.01),预防组分别为2.67±0.25和1.36±0.12(U=24,P<0.05)。(2)模型组血清ALT、AST、FBG、FINS、TNF-α和HOMA-IR水平高于对照组(q值分别为13.130、6.472、6.909、26.619、14.591和49.683,P<0.01)。预防组血清ALT、FINS、FBG、TNF-α和HOMA-IR水平低于模型组(q值分别为7.024、4.145、14.829、13.195和31.991,P<0.01)。(3)模型组血清脂联素、肝组织PPARγ mRNA和蛋白低于对照组(q值分别为10.696、8.679和16.762,P<0.05)。预防组数据高于模型组(q值分别为3.879、3.079、6.400,P<0.05)。HOMA-IR与TNF-α表达呈正相关,但与脂联素表达呈负相关(r=0.927,P<0.01;r=-0.891,P<0.01)。替米沙坦可能通过激活过氧化物酶体增殖物激活受体γ对大鼠非酒精性脂肪性肝炎(NASH)具有预防作用。